💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pravastatin

CHEMBL1144 Phase 4 Đã phê duyệt Small molecule
Half-Life
1.8 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
424.5 g/mol
LogP
1.6
Phase
4

A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.

Khối lượng phân tử

424,5280 g/mol

LogP

1,60

TPSA

124,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Endometriosis Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Alzheimer's Disease Schizophrenia Melanoma Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Hyperlipidemia Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Phân loại thuốc

C — C - Cardiovascular System

Cơ chế tác dụng

Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics (PK)

Half-Life 1.8 hours

Pharmacodynamics (PD)

Cơ chế

Competitive inhibitor of HMG-CoA reductase.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21

                

                

                
                

                    
InChI

                    
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H36O7

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Liên kết có thể quay

                        
11

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
30

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HMGCR (HMG-CoA Reductase)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Pravastatin + Fluconazole
                            
                        

                        
                        
Fluconazole has minimal effect on pravastatin exposure because pravastatin is not significantly metabolised by CYP enzymes; the interaction is pharmacokinetically unimportant in most patients.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Pravastatin + Colchicine
                            
                        

                        
                        
Concurrent use of colchicine and pravastatin carries a small theoretical risk of myopathy, as both drugs individually can cause muscle toxicity, though the combination is better tolerated than colchicine with …

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Pravastatin + Cyclosporine
                            
                        

                        
                        
Cyclosporine inhibits OATP1B1/1B3 hepatic transporters and P-glycoprotein, substantially increasing pravastatin plasma concentrations and raising the risk of myopathy and rhabdomyolysis.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of HMG-CoA reductase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Pravastatin: Half-life: 1.8 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Pravastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1144.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 54687.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.